What CMS Requires: §483.45(c) and F-755
Under 42 CFR §483.45, every skilled nursing facility must provide routine and emergency pharmaceutical services to meet each resident's needs. F-tag 755 is the program-level F-tag that covers that requirement — including the consultant-pharmacist framework, pharmacy contract, emergency medication access, controlled-substance storage, and the drug regimen review (DRR) process itself.
DRR requirements live in §483.45(c)(1)–(4):
| Citation | Requirement | What Surveyors Look At |
|---|---|---|
| §483.45(c)(1) | Consultant pharmacist reviews each resident's drug regimen at least monthly — more frequently for short-stay | Monthly review logs with pharmacist signature for every resident on census |
| §483.45(c)(2) | Irregularity report identifies clinically significant findings (interactions, duplications, excessive dose, missing indication) | Report tied to specific resident, pharmacist-signed, dated |
| §483.45(c)(3) | Irregularity report is acted on by attending physician and DON | Physician response (order change, rationale for inaction), DON follow-up documented |
| §483.45(c)(4) | DRR findings are integrated into the resident's care plan; coverage is bridged across vendor changes | Care plan revisions referencing DRR findings; bridging plan during pharmacy transitions |
F-755 and F-756 are commonly confused. They sit next to each other in the State Operations Manual and both reference the drug regimen review:
- F-755 is the program-level F-tag — did the facility provide pharmaceutical services that meet resident needs, including the framework that supports DRR? Are 24-hour emergency access, the pharmacy contract, controlled-substance reconciliation, and consultant coverage all in place?
- F-756 is the per-resident drug regimen review F-tag — did every resident actually get their monthly pharmacist review, and were the irregularities acted on?
A facility with monthly reviews but no emergency medication supply can be cited at F-755. A facility with strong pharmaceutical services but missed monthly reviews on several residents tends to be cited at F-756. The two F-tags reinforce each other.
How the DRR Process Actually Works
The consultant pharmacist is the engine, but the facility owns the response chain. A well-functioning DRR process has five moving parts running in lockstep:
1. Monthly Pharmacist Review
The consultant pharmacist pulls each resident's medication profile, recent labs, and clinical notes and reviews them against clinical standards. The review covers drug interactions, duplications, dose appropriateness, indication, and adverse event signals. Short-stay residents (anticipated stay of 14 days or fewer for post-hospital rehabilitation) are reviewed on each drug administration or more frequently based on clinical judgment. Every review is documented with the date, pharmacist signature, and the resident identifier.
2. Irregularity Report
Any clinically significant irregularity identified during the review is written up on an irregularity report. The report is tied to the specific resident, names the concern (e.g., "potential bleeding risk — resident on warfarin with concurrent NSAID"), and is dated and signed by the consultant pharmacist. The report is then routed to the attending physician and the DON.
3. Physician Response
The attending physician reviews the report and either takes action (discontinues the medication, changes the dose, orders monitoring labs) or documents a clinically defensible rationale for not changing therapy. Surveyors want a documented response — silence is treated as non-compliance. The timeline is usually short: the regulation doesn't specify a number of days, but surveyor expectations align with the pharmacy contract terms. Most facilities set a 24–72 hour physician response window.
4. DON Follow-Up
The DON reviews the same irregularity report from the operational angle. Did the care plan need to be updated? Are there nursing interventions that need to change? Did the medication administration record need a new risk-monitoring entry? The DON's follow-up is documented separately from the physician response.
5. Care Plan Integration
If the physician changed a medication because of a DRR finding, the care plan has to reflect that change. A care plan that still lists the discontinued medication, or that doesn't reference the new monitoring parameter, is an F-657 gap that compounds the F-755 / F-756 citation.
Surveyor pattern: When DRR findings aren't integrated into the care plan, surveyors cite F-755 (services not meeting resident needs) and F-657 (care plan not revised to reflect clinical changes) in the same deficiency. The two citations are correlated because they describe the same gap from different angles.
Bridging Coverage Across Vendor Changes
A common F-755 citation pattern is the consultant coverage gap. A facility switches long-term care pharmacies and the new vendor's consultant pharmacist comes onboard two weeks late. For those two weeks, no DRRs are being completed. Surveyors will read the pharmacy contract, look at the date the new consultant started, count backwards, and cite the facility for the gap. A bridging plan — the outgoing consultant extending coverage through the transition, or a temporary back-up consultant until the new one starts — neutralizes this risk.
Free: F-755 Drug Regimen Review Checklist
9-page pre-survey audit covering monthly DRR logs, irregularity report routing, physician response chain, DON follow-up, care plan integration, and consultant-coverage bridging. Use it monthly to catch gaps before surveyors do.
What Surveyors Audit for F-755
Surveyors don't just read the pharmacy contract and move on. They trace the DRR process end-to-end, and they do it on a sample of residents — typically residents on high-risk medications, residents with recent medication changes, and short-stay residents. The audit trail they build looks like this:
- Pharmacy contract and consultant agreement — Is there a current contract? Is consultant coverage documented? Is the scope of work (monthly DRR, irregularity reporting, QA reviews) clearly described?
- Monthly DRR logs — Every resident on census during the review window has a dated, pharmacist-signed entry. No skipped months, no unsigned reviews.
- Irregularity reports tied to specific residents — Not a generic facility-wide report. Each finding is tied to the resident's chart with the date and signature.
- Attending physician responses — Order change, monitoring order, or documented rationale for inaction. Timeframe usually under 72 hours.
- DON follow-up documentation — Care plan impact, nursing intervention updates, staff communication documented.
- 24-hour emergency medication access — After-hours pharmacy contact, emergency kit, controlled substance reconciliation.
- Medication storage — Refrigerator temperature logs, controlled substance security, expired medication back-up.
- Care plan integration — If a DRR led to a medication change, the care plan reflects the new medication and the monitoring parameters.
- Vendor/consultant bridging — Coverage plan in place during pharmacy transitions with no DRR gap.
This is why a working F-755 Drug Regimen Review checklist matters: it maps the DRR process to exactly the document path a surveyor will follow, so your pre-survey audit covers the same territory.
Most Common F-755 Deficiencies
Across hundreds of F-tag deficiency citations, the patterns under F-755 and F-756 are remarkably consistent. Here are the ones that keep showing up.
1. Monthly Reviews Overdue for Multiple Residents
The consultant switches mid-quarter, the long-term-care pharmacy drops the ball, or the DON assumes the pharmacist will run the schedule without anyone tracking it. Three months of un-reviewed residents is an immediate-jeopardy-quality citation. CMS doesn't care whose fault it is — the facility is responsible for making sure the reviews happen.
2. Irregularity Reports Not Routed Within the Required Window
The pharmacist identifies a clinically significant issue, writes it up — and the report sits in an inbox for a week. By the time the physician sees it, the resident has been on the at-risk medication for another seven days. The citation writes itself: irregularity report generated, no physician response documented in the required timeframe.
3. No Documented Physician Response
Surveyors see this one constantly. The irregularity report exists. The physician was supposed to respond. There's no order change, no rationale note, nothing. Silence is treated as non-action, and non-action is treated as a deficiency.
4. Care Plan Not Updated After the DRR
The physician changed the medication. The order is in the chart. The MAR reflects the change. But the care plan still has the old medication listed as the primary intervention. That's an F-657 citation stapled onto the F-755 / F-756 finding, and it doubles the severity.
5. No Cover During a Pharmacy Transition
Old pharmacy contract ends March 31. New pharmacy contract starts April 14. Between April 1 and April 13, no DRRs are being completed. Surveyors will ask for the bridging plan and find none.
6. Controlled Substance Reconciliation Gaps
The pharmacy delivers 100 oxycodone tablets. 80 are administered. 5 are documented as destroyed. 15 are "missing." That's storage and accountability failure — and it lands as an F-755 citation even though it's not directly about DRR.
Drug Regimen Review Documentation Checklist
Use this monthly as part of your mock survey process — ideally before the consultant visit, so you can flag gaps while the pharmacist is still on-site:
For each active resident, verify:
- Monthly DRR completed and signed by consultant pharmacist within the current calendar month
- Short-stay reviews at the required increased frequency (per drug administration or pharmacist clinical judgment)
- Irregularities identified produce a dated, pharmacist-signed report tied to the specific resident
- Irregularity report routed to attending physician with response documented within facility timeframe
- Physician response shows order change, monitoring order, or clinically defensible rationale for inaction
- DON follow-up documented — care plan impact, nursing intervention, staff communication
- Care plan updated to reflect any medication change triggered by DRR
- Medication administration record (MAR) matches current orders
- High-risk medications (anticoagulants, antipsychotics, insulin, opioids) have monitoring parameters documented
- Vendor/consultant coverage bridged without gap during any pharmacy transitions in the past 12 months
High-Risk Scenarios Surveyors Probe
Surveyors focus their DRR review on residents who are on anticoagulants with concurrent NSAIDs, residents on multiple psychotropics, residents with recent insulin changes, residents on antibiotics without a documented stop date, and residents who had a recent fall, hospitalization, or significant clinical change. Make sure those charts have a tightly documented DRR and response chain before survey week.
Pharmacy Compliance Bundle — Launching Soon
Drug regimen review, irregularity report templates, physician acknowledgement logs, DON follow-up documentation, and consultant-coverage bridging plans — packaged for monthly use. We're finalizing the package now.
Looking for what's already on the pricing page? See all coming-soon bundles →
Frequently Asked Questions
What is F-tag 755 in a nursing home survey?
F-tag 755 covers the requirement that each SNF provide routine and emergency pharmaceutical services to meet resident needs, including a drug regimen review (DRR) program that meets §483.45(c)(1)–(4). Surveyors cite F-755 when the facility cannot demonstrate a monthly pharmacist-conducted review, when irregularity reports are missing or not routed to the attending physician and DON, or when the facility has no documented response chain back from the prescriber.
How often must a consultant pharmacist review drug regimens in a nursing home?
Under §483.45(c)(1) the consultant pharmacist must review each resident's drug regimen at least once a month. Short-stay residents (anticipated stay of 14 days or fewer for post-hospital rehabilitation) must be reviewed on each drug administration or more frequently per the pharmacist's clinical judgment. The review must produce an irregularity report identifying clinically significant findings.
What is the difference between F-755 and F-756?
F-755 covers the facility's pharmaceutical services program overall — emergency medication access, pharmacy contract, consultant coverage, storage, and the framework that supports drug regimen review. F-756 is the specific Drug Regimen Review F-tag: the resident-level, monthly pharmacist-conducted review and irregularity report chain. Facilities get cited under F-755 for program-level gaps and under F-756 for per-resident review gaps.
Who is responsible for acting on a pharmacist irregularity report?
The attending physician addresses the clinical concern (dose change, medication discontinuation, additional monitoring orders). The DON addresses the operational and care-plan implications. Both responses must be documented. The consultant pharmacist's role is to flag the irregularity; the prescriber and DON carry the action responsibility.
What documentation do surveyors check for F-755 compliance?
Surveyors review the pharmacy contract and consultant agreement, monthly drug regimen review logs, irregularity reports tied to specific residents, attending physician responses, DON follow-up documentation, care-plan revisions triggered by DRR findings, and evidence that pharmaceutical services met resident needs — including emergency medication access, controlled-substance reconciliation, and bridging plans when consultant coverage changed.